



New Company Secretary appointed

Sydney, 30 April 2026: Noxopharm Limited (ASX:NOX) is pleased to announce that Shawn van Boheemen has been appointed as Company Secretary, effective immediately.

Mr van Boheemen is currently Noxopharm's Chief Financial Officer, and he will maintain that role in addition to replacing outgoing Company Secretary David Franks, who has resigned.

Noxopharm would like to thank Mr Franks for all his dedication, hard work and guidance over the years he has been supporting the company, and wishes him well for the future.

Mr van Boheemen has 30 years' experience in commercial finance leadership positions across a range of healthcare, biotech, manufacturing, service-based and financial services industries. This includes Australian ASX and ASIC reporting, SEC reporting in the US, compliance and regulatory affairs, audit (internal and external), taxation, business and financial analytics, intellectual property protection, and regulatory and financial reporting both in Australia and the US.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: +61 425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

Shawn van Boheemen

T: +61 414 903 376

E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will"



or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.